NCT01029314

Brief Summary

Primary study objective is to test the accuracy of the Genius 2 tympanic thermometer and the Exergen TAT-5000(TM) temporal artery thermometer as compared with serial perioperative core temperature measurements obtained in cardiac surgical patients during cardiopulmonary bypass. Study hypothesis: The Genius 2 thermometer will display greater precision and accuracy than the Exergen TAT-5000 thermometer when compared to core body temperature in patients undergoing CABG surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
33

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2008

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2008

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2009

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

December 7, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 9, 2009

Completed
Last Updated

December 9, 2009

Status Verified

December 1, 2009

Enrollment Period

1.1 years

First QC Date

December 7, 2009

Last Update Submit

December 7, 2009

Conditions

Keywords

Thermometry

Outcome Measures

Primary Outcomes (1)

  • Thermometer accuracy and precision: 1) Temperature obtained by Genius 2 and Exergen compared to core body temperature (accuracy). 2) Agreement among temperatures taken in triplicate at a given time point (precision).

    Subjects are followed for temperature collection until 6 hours post admission to the intensive care unit; lab data and patient outcomes are collected until the time of hospital discharge.

Secondary Outcomes (2)

  • Effect of environmental conditions before, during and after surgery, on body temperature and thermometer performance (ambient temperature, humidity, diaphoresis, warming devices).

    Predetermined perioperative time periods up to 6 hours after intensive care unit admission.

  • Explore possible relationships between temperature management and duration of CABG surgery and the following patient outcomes: mortality, renal failure (new onset), stroke, myocardial infarction, length of hospital stay, length of ICU stay.

    Predetermined perioperative time periods until hospital discharge.

Study Arms (1)

Cardiopulmonary bypass surgery

Thirty to fifty cardiac surgery patients undergoing cardiopulmonary bypass will have serial triplicate temperatures taken by both the Genius 2 tympanic thermometer and the Exergen-TAT 5000 temporal artery thermometer at predetermined perioperative time points. These temperature readings will be compared to at least one core temperature (i.e., pulmonary artery).

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults greater than/equal to 18 years of age scheduled for a cardiac surgical procedure requiring cardiopulmonary bypass.

You may qualify if:

  • Male or female adult subjects greater than/equal to 18 years of age providing signed informed consent
  • Febrile or afebrile
  • Planned monitoring of core temperature at a minimum of two separate sites, one of which includes the pulmonary artery
  • Planned use of cardiopulmonary bypass for a cardiac surgical procedure.

You may not qualify if:

  • Mist tents or oxygen hoods
  • Hot or cold applications to the head
  • Patients that have the planned use of deep hypothermic circulatory arrest
  • Aural anomalies (e.g., external auditory canal less than 2cm in length, persistent ear pain)
  • Blood, cerumen, excessive hair, inflammation, infection, ulceration or foreign object in the ear observed by otoscopic examination
  • Any other signs or symptoms of distress or a condition which would, or in the opinion of the principal investigator, render their participation in the study detrimental to their well-being.
  • Previous refusal or enrollment in this study
  • Previous or concurrent participation in a clinical trial of a drug or device within the past 30 days.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

Study Officials

  • Edwin Avery, MD

    Massachusetts General Hospital Corporation

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

December 7, 2009

First Posted

December 9, 2009

Study Start

May 1, 2008

Primary Completion

June 1, 2009

Study Completion

June 1, 2009

Last Updated

December 9, 2009

Record last verified: 2009-12

Locations